Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03637803|
Recruitment Status : Terminated (Sponsor insolvency)
First Posted : August 20, 2018
Last Update Posted : June 1, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This is an open label, safety and preliminary efficacy study of MRx0518 in combination with pembrolizumab in patients with solid tumours (non small cell lung cancer, renal cell carcinoma, bladder cancer or melanoma).
Subjects will be treated with IV pembrolizumab every 3 weeks and 1 capsule twice daily of MRx0518. Treatment will continue as long as clinically relevant, until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years).
|Condition or disease||Intervention/treatment||Phase|
|Oncology Solid Tumor Non Small Cell Lung Cancer Renal Cell Carcinoma Melanoma Bladder Cancer||Drug: MRx0518 Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||63 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Open Label, Safety And Preliminary Efficacy Study of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors|
|Actual Study Start Date :||January 10, 2019|
|Actual Primary Completion Date :||May 8, 2023|
|Actual Study Completion Date :||May 8, 2023|
Experimental: MRx0518 with pembrolizumab
Subjects will receive IV infusion of pembrolizumab once every 3 weeks until disease progression, unacceptable AEs or withdrawal of consent up to a maximum of 35 cycles (approx. 2 years). Starting on the day of first pembrolizumab dose, subjects will take one capsule of MR0518 twice daily until the end of the treatment period.
MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The study dosing regimen is one capsule two times per day for the duration of the treatment period.
Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Pembrolizumab is a potent humanised immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD1) receptor , thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). The study dosing regimen is 200mg (two 4ml vials of 25mg/ml solution) for IV infusion once every three weeks.
- Part A: To assess the safety and tolerability of MRx0518 in combination with pembrolizumab through the collection of adverse events [ Time Frame: Baseline to treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days) ]Adverse events will be assessed as per CTCAE v4
- Part B: To assess safety and tolerability of MRx0518 in combination with pembrolizumab through the collection of adverse events [ Time Frame: Baseline to treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days) ]Adverse events will be assessed as per CTCAE v4
- Part B: To assess the clinical benefit of MRx0518 in combination with pembrolizumab [ Time Frame: Baseline to treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days) ]To determine preliminary evidence of anti-tumor activity
- Antitumour effect [ Time Frame: Baseline and every 3 weeks until treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days) ]Antitumour effect is assessed through tumour imaging and measurement of lesions per RECIST and iRECIST (ORR, DOR, DCR, PFS)
- Biomarkers of treatment effect - blood [ Time Frame: Day 1 of Cycle 1 and Cycle 2 and time of treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days) ]Blood samples will be analysed for changes in immune status and biomarkers of treatment effect
- Biomarkers of treatment effect - tumour [ Time Frame: Baseline, Day 1 of Cycle 4 and time of treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days) ]Tissue biopsies will be taken to analyse for tumour biomarkers
- Microbiota and metabolome [ Time Frame: Day 1 of Cycle 1 and Cycle 2, time of treatment discontinuation up to a maximum of 35 treatment cycles (one cycle = 21 days), and 30 Day follow up ]Faecal and urine samples will be collected and analysed for microbiota and metabolomics using the MicroDx platform
- Overall survival [ Time Frame: From start of treatment until death due to any cause up to a maximum of 35 treatment cycles (one cycle = 21 days) ]Survival of the subjects will be recorded
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Willing and able to provide written informed consent/assent for the trial.
- ≥18 years of age on day of signing informed consent.
- Histological or cytological evidence of advanced and/or metastatic or recurrent NSCLC, renal cell carcinoma, bladder cancer or melanoma.
- At least one measurable lesion per RECIST v 1.1 criteria.
- Failure to respond or intolerance to standard therapy or for whom no appropriate therapies are known to provide clinical benefit (per the judgement of the Investigator).
Subjects must have progressed on treatment with a PD-1/PD-L1 inhibitor administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies. PD-1/PD-L1 inhibitor treatment progression is defined by meeting all of the following criteria:
- Has received at least 2 doses of a PD-1/PD-L1 inhibitor.
- Has demonstrated disease progression after PD-1/PD-L1 therapy as defined by RECIST v1.1, iRECIST or irRECIST. The initial evidence of disease progression (PD) is to be confirmed by a second assessment no less than four weeks from the date of the first documented PD, in the absence of rapid clinical progression.
- Progressive disease has been documented within 12 weeks from the last dose of a PD-1/PD-L1 inhibitor.
- Have adequate organ function
- Be willing to provide archival tissue
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Female subjects of childbearing potential should have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for ≥2 years.
- Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication
- Male subjects with female partners of childbearing potential should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
- Subjects who failed to show any response to initial treatment with PD-1/PD-L1 inhibitor (i.e. no Response or no Stable Disease).
- Has active brain metastases or leptomeningeal disease. Subjects with asymptomatic CNS metastases which have been stable (defined as without evidence of progression by MRI for at least 28 days prior to initiation of therapy and any neurologic symptoms have returned to baseline) following treatment with surgery or radiation therapy are allowed.
- Prior solid organ or hematologic transplant.
- Treatment-related immune-mediated (or immune related) AEs from immune-modulatory agents (including but not limited to anti-PD1/PD-L1 agents, anti-CTLA4 monoclonal antibodies) that caused permanent discontinuation of the agent, or that were grade 3 or 4 in severity.
- Subjects treated with chemotherapy, immunotherapy, biologic therapy, or other investigational agent within <5 times the half-life of the agent or <21 days (whichever is shorter) of starting study drug. Continuation of hormone replacement therapy is permitted. Stable regimens of hormonal therapy i.e. for prostate cancer (e.g. leuprolide, a GnRH agonist), ovarian, or breast cancer are not exclusionary.
- Subjects treated with tyrosine kinase inhibitor therapy or completed palliative radiotherapy <14 days from initiation of therapy.
- Comorbidity requiring corticosteroid therapy (>10mg prednisone/day or equivalent) within 7 days of starting experimental therapy. Physiologic replacement doses are allowed if they are ≤10mg of prednisone/day or equivalent, as long as they are not being administered for immunosuppressive intent. Inhaled or topical steroids are permitted, provided that they are not for treatment of an autoimmune disorder.
- Significant cardiac dysfunction, New York Heart Association classification for chronic heart failure III-IV, symptomatic coronary artery disease, significant ventricular arrhythmias; myocardial infarction within 6 months; unstable, poorly controlled angina pectoris
- Active, known or suspected autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs), except for replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.). Note: corticosteroids given within 24 hours of an imaging study for purposes of pre-medication in subjects with hypersensitivity to radiologic contrast agents are allowed
- Has a serious active infection requiring systemic therapy
- Subjects who have completed a course of antibiotics within the two weeks prior to dosing
- Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the trial
- Receipt of a live-virus vaccination within 28 days of planned treatment start
- Known HIV infection, or active infection with hepatitis A, B or C
- Has a history of (non-infectious) pneumonitis that required steroids or has current active pneumonitis
- Known additional malignancy either progressing r requiring active treatment (except for non-melanoma skin cancer, in situ cervical cancer or prostate intraepithelial neoplasia) within the last 2 years
- Female subjects who are breastfeeding
- Known intolerance or hypersensitivity to study drugs
- Subjects who are allergic to amoxicillin/clavulanic acid, erythromycin and imipenem
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
- Has a known inability for oral intake of capsules
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03637803
|United States, Kansas|
|University of Kansas Medical Center|
|Kansas City, Kansas, United States, 66160|
|United States, Pennsylvania|
|UPMC Hillman Cancer Center|
|Pittsburgh, Pennsylvania, United States, 15232|
|United States, Texas|
|Houston Methodist Cancer Center|
|Houston, Texas, United States, 77030|
|MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|United States, Washington|
|Summit Cancer Center|
|Spokane, Washington, United States, 99208|
|Principal Investigator:||Shubham Pant, MD||M.D. Anderson Cancer Center|
|Responsible Party:||4D pharma plc|
|Other Study ID Numbers:||
Keynote MK3475-823 ( Other Identifier: Merck )
|First Posted:||August 20, 2018 Key Record Dates|
|Last Update Posted:||June 1, 2023|
|Last Verified:||May 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Live Biotherapeutic Product
Carcinoma, Renal Cell
Neoplasms by Site
Neoplasms by Histologic Type
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Male Urogenital Diseases
Neoplasms, Glandular and Epithelial
Antineoplastic Agents, Immunological
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action